The petrelintide Phase 2 trial provides the clearest clinical evidence so far for an obesity-drug approach based on amylin rather than <a href="https://glp1place.com/tools/compound/glp-1/”>GLP-1. In the randomized ZUPREME-1 study, 493 adults with obesity or overweight received once-weekly petrelintide or placebo for 42 weeks, including a dose-escalation period. The strongest treatment group had 10.7% mean weight loss at week 42, compared with 1.7% with placebo. The full report was published on September 29, 2026, in The Lancet Diabetes & Endocrinology.
Petrelintide is not approved for weight management and is not a GLP-1 receptor agonist. It is an investigational, long-acting analogue of amylin, a hormone released by pancreatic beta cells after meals. ZUPREME-1 tested whether this separate satiety-related pathway could support clinically meaningful weight reduction in a controlled trial. The study does not establish that petrelintide is safer, more effective, or more durable than <a href="https://glp1place.com/tools/compound/semaglutide/”>semaglutide, tirzepatide, or any other obesity medicine.
The results are notable for two reasons. First, the study reported weight loss across every petrelintide maintenance-dose group. Second, the average result did not rise in a simple straight line as the dose increased: the 5.0 mg group had the largest mean reduction at the reported week-42 assessment. That pattern may help guide future development planning, but it is not a basis for individual dose selection.
What the petrelintide Phase 2 trial tested
ZUPREME-1 was a multicentre, randomized, double-blind, placebo-controlled Phase 2 dose-finding trial conducted at 32 sites in the United States, Poland, and Romania. It enrolled adults with obesity, defined as a body-mass index of at least 30, or adults with overweight plus weight-related risk factors such as hypertension or dyslipidemia. People with type 2 diabetes were not included.
Participants were randomized in a 5-to-1 ratio to once-weekly subcutaneous petrelintide or placebo. The protocol evaluated five petrelintide maintenance-dose groups: 1.0 mg, 2.5 mg, 5.0 mg, 7.0 mg, and 9.0 mg. Participants began below their assigned maintenance dose and followed a gradual escalation schedule. This was a research-protocol feature intended to assess tolerability as participants moved toward their assigned dose; it is not a treatment recommendation.
The primary efficacy assessment occurred at week 28, while treatment continued through week 42. This longer treatment period allowed investigators to assess whether average weight reduction continued after the initial assessment. The trial also assessed waist circumference, lipid measures, high-sensitivity C-reactive protein, pulse rate, adverse events, and treatment discontinuation.
The peer-reviewed report is available through the Lancet Diabetes & Endocrinology publication. The study record is listed at ClinicalTrials.gov.
Petrelintide Phase 2 trial weight-loss results
Petrelintide produced average weight reductions across all five active-treatment groups. These findings are group averages from a controlled Phase 2 study, not forecasts for a particular person. All participants also received reduced-calorie dietary and increased-physical-activity support, a common element of obesity-drug trials.
| Study group | Mean weight change at week 28 | Mean weight change at week 42 | Reported context |
|---|---|---|---|
| Petrelintide 1.0 mg | About 7.9% reduction | About 8.7% reduction | Weight loss above placebo |
| Petrelintide 2.5 mg | About 7.9% reduction | About 9.2% reduction | Continued average reduction |
| Petrelintide 5.0 mg | About 9.8% reduction | About 10.7% reduction | Largest reported mean result |
| Petrelintide 7.0 mg | About 9.3% reduction | About 10.5% reduction | No clear mean advantage over 5.0 mg |
| Petrelintide 9.0 mg | About 9.4% reduction | About 10.2% reduction | Highest dose was not the top mean result |
| Placebo | About 1.7% reduction | About 1.7% reduction | Trial lifestyle-program background effect |
At week 28, the 5.0 mg group had an approximately 8.1-percentage-point advantage over placebo. At week 42, the largest mean reduction was 10.7% in the 5.0 mg group, compared with 1.7% in the placebo group under the study’s efficacy estimand. An estimand is a prespecified statistical framework that defines the treatment effect a trial intends to estimate, including how treatment interruptions and missing measurements are handled.
That statistical context matters. Weight-loss trials can report different analyses, including analyses that estimate outcomes under continued treatment and analyses that reflect outcomes regardless of whether treatment was interrupted. When comparing reports, readers should consider the outcome definition, follow-up duration, participant population, and handling of missing data rather than comparing headline percentages alone.
Why the highest dose was not the strongest group
It is tempting to expect a simple dose-response relationship in which the highest dose always produces the most weight loss. ZUPREME-1 did not show that pattern. The 7.0 mg and 9.0 mg groups had substantial mean reductions, but neither clearly exceeded the 5.0 mg group’s mean result at week 42.
Several explanations are possible, and the study was not designed to settle all of them. Amylin-related biology may reach a practical efficacy plateau within the studied range. Differences between Phase 2 groups may also reflect ordinary statistical variation, adherence patterns, tolerability, or participant characteristics. A dose-finding study helps select regimens for later research; it does not define a final regimen for routine clinical practice.
The result is still relevant to Phase 3 planning. Developers need to assess not only average weight change, but also adverse events, treatment persistence, longer-term safety, manufacturing practicality, and the relative benefit of higher exposure. A higher dose would not necessarily be preferable if it did not produce a meaningful additional average benefit in larger studies.
Petrelintide side effects and tolerability findings
Gastrointestinal tolerability was a major focus of ZUPREME-1. The overall pattern included gastrointestinal adverse events. Nausea occurred in approximately 20% of participants receiving petrelintide, compared with about 6% receiving placebo. Constipation was also somewhat more common in the petrelintide groups.
Vomiting was not increased over placebo in the reported overall study pattern. In the 5.0 mg group, investigators reported no vomiting events and no gastrointestinal adverse-event discontinuations. These findings apply to the study population and protocol, but they should be interpreted narrowly. A 493-person Phase 2 trial cannot establish the frequency of uncommon harms or prove a comparative tolerability advantage over approved medicines.
ZUPREME-1 did not directly compare petrelintide with semaglutide, tirzepatide, cagrilintide, or another active treatment. Cross-trial comparisons can mislead because studies differ in participant characteristics, eligibility criteria, dose-escalation schedules, follow-up length, adverse-event collection, lifestyle intervention, and statistical analysis. The evidence-based conclusion is that petrelintide showed meaningful weight loss with gastrointestinal adverse events that appeared manageable in this trial, not that it has been proven easier to tolerate than another therapy.
How petrelintide differs from GLP-1 medicines
Amylin is a hormone produced by pancreatic beta cells and released with insulin after eating. It contributes to meal-related satiety and influences gastric emptying. Petrelintide is designed to mimic important actions of human amylin while maintaining activity compatible with once-weekly study administration.
GLP-1 receptor agonists work through a different receptor system. Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates GLP-1 and GIP receptors. Petrelintide instead targets amylin-related signaling. It belongs to the broader metabolic-medicine pipeline, but it is not another GLP-1 drug.
A distinct mechanism is scientifically relevant, but it does not itself establish a clinical advantage. Some people may respond differently to different biological pathways, and complementary mechanisms may eventually be evaluated together in controlled research. However, ZUPREME-1 studied petrelintide monotherapy. It provides no evidence supporting self-directed combinations of petrelintide with investigational or approved medicines.
Roche and Zealand Pharma are also studying broader metabolic approaches involving enicepatide, also known as RO7795068 or CT-388. That separate development work should not be conflated with ZUPREME-1. The trial reported here tested petrelintide alone against placebo.
Cardiometabolic findings beyond body weight
Weight change was the central outcome, but ZUPREME-1 also reported secondary cardiometabolic findings. Petrelintide was associated with reductions in waist circumference, triglycerides, and high-sensitivity C-reactive protein. High-sensitivity C-reactive protein is a blood marker associated with systemic inflammation, while triglycerides are circulating blood fats linked with cardiometabolic risk.
The largest reported average reduction in waist circumference was approximately 10.8 cm, compared with about 4.3 cm for placebo. High-sensitivity C-reactive protein fell by as much as 41% in a petrelintide group, compared with approximately 6% with placebo. Triglycerides decreased by up to about 21%, compared with approximately 9% with placebo.
These results are consistent with changes that can accompany weight loss, but they should not be interpreted as evidence that petrelintide prevents heart attacks, strokes, kidney disease, or death. Such outcomes require larger, longer trials with prespecified clinical endpoints. They also do not establish that the effects are independent of weight reduction.
Total body weight is only one measurement in obesity research. Waist circumference, fat mass, lean mass, metabolic markers, physical function, and long-term clinical outcomes answer different questions. GLP1Place has separately reviewed evidence on body-composition changes during GLP-1 research; that context is useful when evaluating what a scale-based trial result can and cannot show.
How ZUPREME-1 fits the obesity-drug pipeline
Petrelintide enters a rapidly expanding obesity-research field that includes GLP-1 medicines, dual and triple receptor agonists, oral candidates, and approaches intended to address body composition or long-term treatment persistence. Its differentiating feature is its amylin-based mechanism, not demonstrated superiority over competing investigational programs.
Results cannot be ranked reliably by placing headline weight-loss percentages side by side. Trials in adults with type 2 diabetes often differ from trials in adults without diabetes. Treatment duration, baseline body weight, lifestyle support, dose escalation, discontinuation rates, analysis rules, and population characteristics can all influence reported averages.
Petrelintide’s approximately 10.7% mean weight reduction at week 42 was lower than some headline results reported for certain next-generation incretin agonists in other studies. Its potential role will depend on whether Phase 3 research confirms efficacy, safety, durability, and an acceptable balance of benefits and adverse events. Future comparative or combination trials may also help clarify where an amylin analogue could fit in clinical practice.
GLP1Place has reviewed early evidence for ribupatide and clinical findings for BGM0504. Those reports provide pipeline context but are not direct comparators for ZUPREME-1.
What the ZUPREME-1 study does and does not prove
ZUPREME-1 has several methodological strengths. It was randomized, double-blind, placebo-controlled, and multicentre. It tested five active maintenance-dose groups and continued treatment beyond the primary week-28 assessment. The peer-reviewed report also provides more detail than a company announcement alone.
Its limitations are equally important. It was a Phase 2 study rather than a definitive registration trial. It excluded people with type 2 diabetes, so the findings do not automatically apply to that population. It had no active comparator, followed participants for 42 weeks, and was not designed to detect cardiovascular events, mortality effects, or all uncommon adverse events. Zealand Pharma funded the study, and petrelintide is being developed with Roche; that funding relationship should be considered alongside the peer-reviewed methods and results.
The study included participants in three countries, but broader Phase 3 programs will be needed to evaluate results across more diverse populations and common obesity-related medical conditions. Average outcomes also do not show the full distribution of individual responses, including who had little response, who discontinued treatment, or how weight changed after treatment ended.
What happens next for petrelintide research
Following ZUPREME-1, Zealand Pharma and Roche advanced petrelintide into a global Phase 3 program for chronic weight management. Phase 3 studies are generally larger and longer than Phase 2 trials and are intended to provide the evidence regulators review when assessing effectiveness and safety.
Important questions remain. Researchers will need to assess whether weight reduction is maintained beyond one year, what happens after treatment discontinuation, and how petrelintide performs in people with type 2 diabetes, cardiovascular disease, and other common obesity-related conditions. Larger studies should also provide more information on body composition, gallbladder events, pancreatic outcomes, nutritional effects, lean-mass changes, and uncommon adverse events.
Petrelintide remains investigational and is not an FDA-approved product. The appropriate next step is controlled clinical research, not consumer experimentation with unapproved products or untested combinations.
Researcher takeaways
The petrelintide Phase 2 trial shows that an amylin-based approach produced substantial mean weight loss in adults with obesity or overweight without type 2 diabetes. The largest reported average reduction was 10.7% at week 42 in the 5.0 mg group, versus 1.7% with placebo.
The study also illustrates why obesity-drug research should not be judged by weight change alone. Petrelintide’s future will depend on longer-term safety, treatment persistence, body-composition findings, durability, and results in broader populations. The Phase 3 program will determine whether this Phase 2 signal can support a durable clinical role.
Frequently asked questions
What did the petrelintide Phase 2 trial find?
The ZUPREME-1 Phase 2 trial found that once-weekly petrelintide produced up to 10.7% mean weight loss at week 42, compared with 1.7% for placebo. The largest average result occurred in an intermediate dose group rather than the highest dose tested.
Is petrelintide a GLP-1 drug?
No. Petrelintide is an investigational long-acting analogue of amylin, a hormone released by pancreatic beta cells after meals. It uses a different mechanism from GLP-1 receptor agonists such as semaglutide.
Did petrelintide cause fewer side effects than semaglutide or tirzepatide?
ZUPREME-1 did not directly compare petrelintide with semaglutide or tirzepatide. Nausea was more common with petrelintide than placebo, while vomiting and gastrointestinal discontinuations were relatively uncommon in the study. A direct comparison would be needed to establish relative tolerability.
Is petrelintide approved for weight loss?
No. Petrelintide remains investigational and is not FDA approved. The Phase 2 findings support further research but do not establish long-term safety, cardiovascular benefit, or effectiveness in every patient population.
What happens next for petrelintide?
Zealand Pharma and Roche have advanced petrelintide into a global Phase 3 development program for chronic weight management. Those trials are expected to provide larger and longer-term evidence on safety, durability, and clinically important outcomes.